This week's screen surfaced five companies trading well below where analyst consensus sits: Ionis Pharmaceuticals, Paramount Skydance, Sarepta Therapeutics, Devon Energy and FMC. The implied upside runs from 41.6% to 65.1%, a tight enough band that ranking them by percentage tells you almost nothing. What separates them is the shape of the target distribution behind each average, and on that measure the five are not remotely alike.
The analysis begins with FMP's Price Target Summary Bulk API, which consolidates consensus targets and coverage counts across a broad ticker set in a single call. This article uses it to identify the gaps, then looks past the headline spread at the high and low targets underneath, because a wide gap built on agreement and a wide gap built on two incompatible scenarios are different objects entirely.
Key Takeaways
- All five gaps fall between 41.6% and 65.1%, so the percentage alone does not distinguish them; the ratio of high target to low target does, and it ranges from 1.26 to 2.50 across the group.
- Devon Energy's targets cluster tightly, which makes its gap a shared view about capital allocation credibility rather than a disagreement about the underlying business.
- Sarepta and Paramount Skydance carry event-contingent gaps where the consensus average describes a scenario no individual analyst is actually modelling.
Where Price and Consensus Sit Furthest Apart
Ionis Pharmaceuticals, Inc. (IONS)
Current Price: $56.56 • Consensus Target: $93.36 • Upside Potential: 65.1%
Nothing in the reported numbers obviously explains why Ionis carries the widest gap in the screen. First-half revenue reached $514 million, split between $226 million of commercial revenue growing 27% and $288 million from partnered research programmes, and the quarter beat expectations by a wide margin. Full-year revenue guidance sits at $875 million to $900 million, implying growth above 30%, with $2.1 billion of cash and short-term investments on the balance sheet and a stated 2028 cash flow breakeven target. Shares fell anyway.
The disagreement is about the path rather than the destination. Ionis is running several commercial launches at once, and the early revenue figures are small relative to the guided full-year numbers: roughly $32 million of first-half sales against a $100 million to $110 million target for one product, and $42 million against a $110 million to $120 million target for another. Both imply a substantial second-half acceleration. Concerns raised after the print centred on reimbursement friction rather than clinical performance, which is a distinction worth holding onto, because a coverage bottleneck shows up as a lag between prescriptions written and prescriptions filled rather than as weak demand.
The calendar is also unusually dense, with a regulatory decision due in late September and Phase 3 readouts across several programmes, so the target distribution spans $69 to $115. That 1.67 ratio suggests analysts broadly agree the company gets there and disagree on when. FMP's Financial Estimates API is the dataset that makes this legible, since the question is whether forward revenue estimates are being pushed later in the model or reduced outright, and those two adjustments look identical in a headline target but mean very different things.
Paramount Skydance Corporation (PSKY)
Current Price: $9.19 • Consensus Target: $14.00 • Upside Potential: 52.3%
Paramount Skydance produces a 52.3% gap on a business that is, by the quarter's evidence, executing. Paramount+ reached close to 82 million subscribers on its strongest retention quarter to date, direct-to-consumer revenue grew 16%, and the studio segment returned to profitability with $36 million of adjusted operating income against losses a year earlier. Management raised full-year adjusted EBITDA guidance to $3.8 billion to $3.9 billion and lifted free cash flow conversion guidance, with more than $2.7 billion of run-rate efficiencies expected by year end against a $3 billion-plus synergy target.
None of that is what the target gap is measuring. The consensus number reflects a company that includes Warner Bros. Discovery, while the share price reflects the probability that the acquisition completes and the cost of waiting for it. The company has secured regulatory clearance across 65 jurisdictions, but litigation scheduled for March 2027 leaves the timeline unresolved, and the delay is quantified with unusual precision: roughly $190 million of additional financing costs through June 2027, plus quarterly ticking fees of $650 million payable to the target's shareholders if closing extends beyond the end of September.
That last figure is the analytically useful one, because it converts an open-ended timing risk into a measurable quarterly cost. With targets spanning $10 to $18, the consensus of $14 sits between two scenarios rather than describing either. FMP's Enterprise Values API is the right reference point here, since the equity value is a residual after financing that is still being negotiated, and the debt and enterprise-value figures move first when the deal timeline shifts.
Sarepta Therapeutics, Inc. (SRPT)
Current Price: $16.78 • Consensus Target: $25.11 • Upside Potential: 49.6%
Estimates on Sarepta run from $14 to $35, the most dispersed target set in the screen. A high-to-low ratio of 2.50 means the consensus figure of $25.11 is an arithmetic result rather than an opinion, and treating it as a central case would misread the situation entirely. The screen has surfaced a binary, and the average of a binary is a number nobody is forecasting.
The quarter shows why the distribution split. Total revenue of $401.3 million fell 34% year over year but exceeded expectations, and the composition tells the story: the gene therapy contributed $98.1 million against $281.9 million a year earlier, while the antisense oligonucleotide portfolio held essentially flat at $230.6 million versus $231.3 million. A regulatory label restriction removing the non-ambulatory indication, imposed after acute liver failure cases, is the cause of the decline. Full-year net product revenue guidance was narrowed to $1.2 billion to $1.3 billion from a wider prior range.
So one part of the business is a stable base and the other is contingent on a regulatory question that will not resolve quickly. A new immunosuppressive regimen study is expected to finish enrolling by year end, with twelve-week safety data anticipated in the first quarter of 2027 for discussion with regulators, which places the decision point more than two quarters out. Management did note sequential growth in patients enrolling, so demand has not disappeared. FMP's Revenue Product Segmentation API is the dataset that separates these two components cleanly, because a consolidated revenue line blends a durable franchise with an option that is currently out of the money.
Devon Energy Corporation (DVN)
Current Price: $42.98 • Consensus Target: $61.15 • Upside Potential: 42.3%
Devon is the outlier in this group, and the reason is the shape of its target set rather than its size. Estimates run from $54 to $68, a high-to-low ratio of just 1.26, which is the tightest clustering in the screen by a wide margin.
The operating quarter gives that consensus something to stand on. Devon generated $1.7 billion of adjusted free cash flow with oil production of 503,000 barrels per day, above guidance, and total volumes of 1.36 million barrels of oil equivalent per day at the top end of the range. Capital spending came in 2.4% below forecast at $1.3 billion, which pulled the reinvestment rate down to 43% from the mid-fifties in prior years. The quarterly dividend rose 33% to $0.32, more than $1 billion was returned to shareholders in the final seven weeks of the quarter, and $7.8 billion of repurchase authorisation remains. Management reiterated confidence in the $1 billion synergy target from the Coterra combination, with more than 350 initiatives identified.
Management themselves named the disconnect, attributing the share price lag to uncertainty about strategic direction rather than about results, and committed to a portfolio review in the autumn with the framing that every asset has to earn its place. That makes this a capital allocation question rather than an operating one, which is a narrower and more checkable thing. FMP's Key Metrics TTM API is where it gets measured, since free cash flow yield, returns on capital and the reinvestment rate are the metrics that would show whether the allocation discipline described in the quarter persists across the next few.
FMC Corporation (FMC)
Current Price: $10.59 • Consensus Target: $15.00 • Upside Potential: 41.6%
The narrowest gap in the screen belongs to FMC, and it is also the one least driven by operations. Second-quarter revenue of $867 million declined 17%, falling 20% excluding the India business, on lower diamide and legacy product volumes alongside pricing pressure across every region. Adjusted EBITDA fell 26% to $153 million, though it did come in above the top of the guided range, helped by $62 million of raw material and supply chain savings. Full-year guidance now points to revenue of $3.50 billion to $3.70 billion and adjusted EBITDA of $620 million to $680 million, with management describing 2026 as a trough year.
The balance sheet is what makes the target gap behave the way it does. Net debt stands at $3.8 billion against trailing EBITDA that implies leverage of 5.1 times. At that level the equity is a thin residual, so a modest change in the EBITDA assumption moves the implied share price disproportionately, which is also why the target range runs from $11 to $21 on a $10.59 price. Analysts are not disagreeing about the agricultural chemicals cycle by a factor of two. They are applying similar operating views to a capital structure that amplifies them.
One detail deserves care in reading the cash flow improvement. Free cash flow rose to $357 million from $40 million, a $318 million swing, but that figure includes a $200 million upfront licensing payment and a working capital release, so it is not a run-rate. Gross debt fell $250 million and management has flagged close to $1 billion of planned asset sales and partnerships, which is the actual deleveraging mechanism. FMP's Balance Sheet Statement API is the appropriate place to follow this, because the equity story here is a debt story first, and the relevant evidence is whether the leverage multiple falls on sustained EBITDA rather than on one-time proceeds.
Why Five Similar Gaps Are Not One Signal
Ranked by upside, these five names occupy a narrow band between 41.6% and 65.1%, which is exactly the situation where a target-gap screen is most likely to mislead. Ranked by target dispersion, they separate immediately. Devon sits at a 1.26 high-to-low ratio, Ionis at 1.67, Paramount Skydance at 1.80, FMC at 1.91 and Sarepta at 2.50. That second ordering carries the information the first one does not, because it distinguishes a gap analysts agree on from an average sitting between two scenarios that cannot both be true.
Read that way, the group contains three different structures. Devon and Ionis are timing disagreements against a defined plan, where consensus accepts the destination and the market is discounting the route. Paramount Skydance and Sarepta are event-contingent, with a transaction and a regulatory decision respectively doing the work, and in both cases the consensus figure is an artifact of averaging incompatible outcomes rather than a forecast. FMC is neither: its dispersion comes from leverage amplifying ordinary differences in an operating view. Applying the same threshold rule to all five would treat these as one phenomenon.
Testing which is which needs more than the target feed. Pairing the Price Target Summary Bulk API with the Financial Estimates API shows whether forward revenue and EPS assumptions are being deferred or reduced, which is the specific check that separates a timing gap from a deteriorating one. The Income Statement API and Cash Flow Statement API together establish whether reported improvement is reaching cash, which is what flags the one-time licensing payment inside FMC's cash flow swing before it gets extrapolated. The wider dataset coverage available through FMP is what allows those checks to run against the same timestamp rather than across four separately maintained pulls, which is where most of the reconciliation cost in this kind of screen actually sits.
Two further layers are worth adding once the gap is classified. Key Metrics TTM normalises leverage, returns and free cash flow yield across businesses with nothing in common, which matters when one screen has produced two biotechs, a media company, an oil producer and an agricultural chemicals business. The Earnings Surprises API then shows whether the companies have been beating or missing the estimates those targets rest on, and a wide gap sitting on a record of consistent misses is a different proposition from the same gap on a record of beats. The practical conclusion is that the percentage identifies candidates and the distribution behind it determines which ones are worth the research time.
Creating a Structured Target-Gap Workflow
A price-target spread only becomes useful when the calculation can be reproduced reliably. That means fixing the data inputs, pulling them in a consistent sequence, and applying the same formula every time the screen runs. Once those elements are standardized, the exercise stops being a one-off comparison and turns into a process that can be refreshed on a schedule.
The only requirement before running the workflow is a valid API key.
Step 1: Pull Analyst Price Targets
The process starts by establishing where consensus currently sits. This is done by querying the Price Target Summary Bulk API, which returns average price targets along with analyst participation counts across the ticker set in a single call. That combination matters: the average target provides the reference level, while coverage depth helps contextualize how representative that number is. Together, they form the baseline against which market prices will be compared.
Endpoint:
|
https://financialmodelingprep.com/stable/price-target-summary-bulk?apikey=YOUR_API_KEY |
Sample Response:
|
[ { "symbol": "AAPL", "lastQuarterCount": "12", "lastQuarterAvgPriceTarget": "228.15", "lastYearAvgPriceTarget": "205.34" } ] |
Step 2: Pull Latest Market Prices
Once targets are in place, the next input is the current trading price. This comes from the Company Profile Data API, which includes the most recent quote used for comparison. At this stage, the goal isn't granularity or intraday precision — it's simply to anchor each name to the same market reference point so gaps are calculated consistently.
|
https://financialmodelingprep.com/stable/profile/AAPL?apikey=YOUR_API_KEY |
Step 3: Derive the Target Gap
Once both values are available, the gap itself is straightforward to compute. Express it as a percentage to normalize results across different price levels:
Upside % = (Price Target - Current Price) / Current Price × 100
Using percentages allows large-cap and lower-priced names to sit in the same ranking without distortion.
Step 4: Apply a Threshold Filter
The final layer is judgment. Most workflows introduce a minimum threshold — often around 20% — to filter out routine variance and focus attention on gaps that are large enough to matter. At this stage, analyst coverage becomes part of the interpretation: a wide gap backed by broad, recent coverage carries a different weight than one driven by a small or outdated estimate set.
Structured this way, the process moves beyond a simple valuation screen. It becomes a repeatable diagnostic tool — one that highlights where price and consensus are drifting apart and does so in a way that can be refreshed, audited, and scaled across time and coverage universes.
From Individual Screen to Institutional Research Process
Most quantitative workflows begin quietly — a model or screen built by a single analyst to answer a recurring question with greater consistency. The first version usually lives in a spreadsheet or a small script: efficient, practical, and tailored to the needs of one desk. The turning point arrives when the signal proves useful enough that colleagues begin asking for it. Replication follows, and with it comes an unintended side effect: slight variations in endpoints, refresh schedules, or calculation logic start producing subtly different results.
At that stage, the analyst who created the workflow often becomes an informal architect of standardization. The challenge shifts from running the screen to defining the method behind it. Institutional value emerges when the process is formalized: the data sources are fixed, the sequence of API pulls is documented, formulas are locked, and thresholds are explicitly defined. Once those elements are stabilized, the workflow stops being a personal tool and begins to function as a shared research input.
Moving the process into a centralized dashboard with scheduled updates is usually the next step in that evolution. Instead of circulating spreadsheets or ad-hoc scripts, teams interact with the same data pipeline and the same calculation framework. This reduces workflow fragmentation across research groups and allows portfolio managers, analysts, and risk teams to reference the same signal simultaneously. When everyone is drawing from the same dataset and methodology, discussions shift away from reconciling numbers and toward interpreting what the signal actually means.
Standardization also strengthens governance and transparency. A centralized workflow creates a visible audit trail: where the data originated, when it refreshed, and how each metric was derived. That lineage matters in institutional environments where reproducibility is essential. When colleagues run the same query and obtain the same result, the signal becomes dependable infrastructure rather than a one-off analytical shortcut.
Scaling that kind of workflow across a team requires stable access to the underlying datasets and consistent distribution across users. Infrastructure becomes less about adding features and more about removing friction from the research process. Platforms designed for institutional usage — such as FMP's Enterprise plan — provide the access controls, refresh stability, and shared environment needed when a desk-level workflow transitions into a broader research tool.
When that transition happens successfully, the model itself changes role. The target-gap screen is no longer simply a clever comparison between price and analyst targets. It becomes part of the firm's analytical framework — a standardized diagnostic that multiple teams can rely on to identify where market pricing and consensus expectations are beginning to drift apart.
What the Distribution Says Next
The useful output of this week's screen is not five upside percentages but five differently shaped disagreements, each with its own resolution point: a regulatory calendar, a court date, an autumn portfolio review, a deleveraging path. FMP's Price Target Summary Bulk API keeps the detection consistent from week to week, which is what makes it possible to watch whether those distributions tighten or split further as each of those dates arrives.
If you enjoyed this analysis, you'll also want to read: Weekly Signals Desk | Five Notable Valuation Disconnects from the FMP API (July 27-31)
Disclosure: Signals Desk content is provided for informational and analytical purposes only and does not constitute investment advice or trade recommendations. The analysis reflects interpretation of market data and publicly disclosed or third-party information, including data accessed via Financial Modeling Prep APIs, at the time of publication. Signals discussed are probabilistic, can be wrong, and may change as market conditions and consensus data evolve. This content should be considered alongside broader research, individual objectives, and risk assessment.
